Literature DB >> 18001617

Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence.

Daniel A Duprez1.   

Abstract

Arterial hypertension is one of the most important preventable causes of death worldwide; therefore, adequate treatment of high blood pressure should be mandatory in each hypertensive patient. Hypertension is now defined on the basis of systolic and diastolic blood pressure levels and classified into stages on the basis of the degree of elevation. Normal blood pressure is widely considered as being less than 120/80 mm Hg. The presence of risk factors such as elevated blood cholesterol, smoking, diabetes, and obesity greatly increases the risk for hypertension-related morbid events. The physiologic link between vascular health and arterial pressure makes it difficult to separate the adverse effects of pressure and vascular functional and structural alterations in determining the adverse complications of hypertension. Several landmark trials in hypertension treatment have been published in the past few years, providing more evidence-based medicine data regarding optimal treatment of hypertension to reduce cardiovascular morbidity and mortality. Maintaining vascular health within the scope of global risk reduction in a personalized manner will be the cornerstone of modern cardiovascular disease prevention rather than waiting until arterial hypertension develops.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001617     DOI: 10.1007/s11883-007-0045-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  31 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Is it the blood pressure or the blood vessel?

Authors:  Jay N Cohn
Journal:  J Am Soc Hypertens       Date:  2007 Jan-Feb

Review 3.  Monitoring vascular health beyond blood pressure.

Authors:  Daniel A Duprez; Jay N Cohn
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

4.  Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects.

Authors:  John Dernellis; Maria Panaretou
Journal:  Hypertension       Date:  2005-02-14       Impact factor: 10.190

5.  Arterial stiffness and the development of hypertension. The ARIC study.

Authors:  D Liao; D K Arnett; H A Tyroler; W A Riley; L E Chambless; M Szklo; G Heiss
Journal:  Hypertension       Date:  1999-08       Impact factor: 10.190

6.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

7.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

8.  Prehypertension and cardiovascular disease risk in the Women's Health Initiative.

Authors:  Judith Hsia; Karen L Margolis; Charles B Eaton; Nanette K Wenger; Matthew Allison; LieLing Wu; Andrea Z LaCroix; Henry R Black
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

9.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

10.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

View more
  1 in total

Review 1.  Rationale for triple-combination therapy for management of high blood pressure.

Authors:  Alan H Gradman
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-20       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.